# BLOOD PRESSURE VS ALTITUDE IN HYPERTENSIVE AND NON-HYPERTENSIVE HIMALAYAN TREKKERS

T. Douglas Sallade<sup>1</sup>, Alison Sheets<sup>2</sup>, Jennifer Starling<sup>3</sup>, David Young<sup>3</sup>, David Twillman<sup>3</sup>, Nirajan Regmi<sup>4</sup>, Benoit Phelan<sup>5</sup>, Purshotam Paudel<sup>6</sup>, Sushil Pant<sup>7</sup>, Matthew McElwee<sup>8</sup>, Theodore McConnell<sup>9</sup>, Luke Mather<sup>10</sup>, Charles Duke<sup>11</sup>, Devlin Cole<sup>8</sup>, Buddha Basnyat<sup>4</sup> and Linda E. Keyes<sup>3</sup>

<sup>1</sup>Philadelphia College of Osteopathic Medicine; <sup>2</sup>Longmont United Hospital; <sup>3</sup>University of Colorado; <sup>4</sup>Nepal International Clinic; <sup>5</sup>Dalhousie University; <sup>6</sup>Tribhuvan University; <sup>7</sup>Kunde Hospital; <sup>8</sup>Case Western University; <sup>9</sup>McGill University; <sup>10</sup>University of Washington; <sup>11</sup>University of Tennessee

### Introduction

- Hypertension is the most common cardiovascular disease found in individuals recreating at high altitudes.<sup>1</sup>
- Evidence is conflicting on how blood pressure (BP) changes with altitude in hypertensive (HTN) and normotensive (NTN) individuals.
- Most studies are done at altitudes <3500m using small numbers of subjects.<sup>2</sup>
- In NTNs, acute hypoxia causes increased, decreased, or unchanged BP; in HTNs, BP may increase and then gradually decline.<sup>2</sup>
- Evidence for efficacy of BP medication at altitude is limited.
- There is no evidence ACEIs effectively control BP in HTNs at altitude.
- ARBs control BP <3400m but does not at higher elevations in NTNs.<sup>3</sup>
- Selective and non-selective β-blockers blunt rising BP in NTNs traveling to altitude.<sup>4,5</sup>

# Objectives

- Determine how BP changes in HTN and NTN trekkers at altitude.
- Determine effectiveness of antihypertensive medications at altitude.

### Methods

- This study was a prospective, observational cohort carried out in the Khumbu Valley of Nepal, en route to Everest Base Camp. October-November 2014.
- Demographics, anthropometrics, medical history and medication use was gathered.
- Manual BP was measured in the same arm at 2800m, 3400m, and 4400m.


#### **Contact Information**

Acknowledgements


Altitude	HTN (n=60)	NTN (n=604)	
2800m	58	601	
3400m	42	479	
4400m	25	335	

**Subjects** 

#### **Blood Pressure Did Not Change** with Altitude in HTN and NTN Trekkers



#### Severe Hypertension (>180/100) Found **Most Frequently in HTN Trekkers Across Altitudes** Relative Risk (5.59; 95% CI 3.47-9.02)



## Results


#### HTN Trekkers Older, More Overweight

	HTN	NTN		
Gender	M = 43 F = 17	M = 346 F = 257		
Age (years)	58	47		
BMI	25	24		

#### Direction of BP Change Varied, **More Likely to Decrease in HTN Trekkers**

2800m to 3400m		3400m to 4400m			
Δ SBP (mmHg)	HTN	NTN	ΔSBP (mmHg)	HTN	NTN
Δ<-10	39%	23%	Δ<-10	35%	20%
-10<Δ<10	37%	51%	-10<Δ<10	39%	54%
Δ>10	24%	26%	Δ>10	26%	26%

#### Severe Hypertension (>180/100) Found **Most Frequently In HTN Trekkers Taking ACEIs and Thiazides**



# Conclusions

- BP change with altitude is variable in individual trekkers; decreased BP with ascent is more likely in HTN trekkers than NTN trekkers, but demographic and anthropometric differences may exist between the cohorts.
- Severe hypertension is more common in HTN trekkers than NTN trekkers but was asymptomatic in all cases.
- Subjects on ACEIs and thiazides were more likely to have severe hypertension than those on other medications.
- Further study is required to determine the clinical importance of these findings.

# References

<sup>1</sup>Faulhaber M, Gatterer H, Burtscher M. Preexisting cardiovascular diseases among high-altitude mountaineers. J Travel Med. 2011 Sep-Oct;18(5):355-7.

<sup>2</sup>Luks, AM. Should Travelers with Hypertension Adjust Their Medications When Traveling to High Altitude?. High Alt Med Biol. 10.1 (2009): 11-15.

<sup>3</sup>Parati G, Bilo G, Faini A, Bilo B, Revera M, Giuliano A, Lombardi A, Caldara G, Gregorini F, Styczkiewicz K, Zambon A, Piperno A, Modesti PA, Agostoni P, Mancia G. Changes in 24 h ambulatory blood pressure and effects of angiotensin II receptor blockade during acute and prolonged high-altitude exposure: a randomized clinical trial. Eur Heart J. 2014 Aug.

<sup>4</sup>Wolfel EE, Selland MA, Mazzeo RS, Reeves JT. Systemic hypertension at 4,300m is realted to sympathoadrenal activity. J of Appl Physiol. 1994 Apr. 76 (4) 1643-1650. <sup>5</sup>Bilo G, Caldara G, Styczkiewicz K, Revera M, Lombardi C, Giglio A, Zambon A, Corrao G, Faini A, Valentini M, Mancia G, Parati G. J Hypertens. 2011 Feb; 29(2):380-7.

T. Douglas Sallade Linda Keyes, MD linda.keyes@gmail.com tdsallade@gmail.com

**Wilderness Medicine Society Nepal International Clinic**